First-line systemic treatment strategies for unresectable hepatocellular carcinoma : A cost-effectiveness analysis
Copyright: © 2023 wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited..
BACKGROUND: Oral multikinase inhibitors and immune checkpoint inhibitors (ICIs) are effective for treating advanced hepatocellular carcinoma (aHCC) but may increase cost. This study compared the cost-effectiveness of oral multikinase inhibitors and ICIs in the first-line treatment of patients with aHCC.
METHODS: A three-state Markov model was established to study the cost-effectiveness of drug treatment from the perspective of Chinese payers. The key outcomes in this study were total cost, quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER).
RESULTS: The total costs and QALYs of sorafenib, sunitinib, donafenib, lenvatinib, sorafenib plus erlotinib, linifanib, brivanib, sintilimab plus IBI305, and atezolizumab plus bevacizumab were $9070 and 0.25, $9362 and 0.78, $33,814 and 0.45, $49,120 and 0.83, $63,064 and 0.81, $74,814 and 0.82, $81,995 and 0.82, $74083 and 0.85, and $104,188 and 0.84, respectively. The drug regimen with the lowest ICER was sunitinib ($551 per QALY), followed by lenvatinib ($68,869 per QALY). For oral multikinase inhibitors, the ICER of lenvatinib, sorafenib plus erlotinib, linifanib and brivanib compared with sunitinib was $779576, $1534,347, $1768,971, and $1963,064, respectively. For ICIs, sintilimab plus IBI305 is more cost effective than atezolizumab plus bevacizumab. The model was most sensitive to the price of sorafenib, the utility of PD, and the price of second-line drugs.
CONCLUSION: For oral multikinase inhibitors, the order of possible treatment options is sunitinib > lenvatinib > sorafenib plus erlotinib > linifanib > brivanib > donafenib. For ICIs, the order of possible treatment options is sintilimab plus IBI305 > atezolizumab plus bevacizumab.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
---|---|
Enthalten in: |
PloS one - 18(2023), 4 vom: 13., Seite e0279786 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wang, Liting [VerfasserIn] |
---|
Links: |
---|
Themen: |
2S9ZZM9Q9V |
---|
Anmerkungen: |
Date Completed 17.04.2023 Date Revised 26.04.2023 published: Electronic-eCollection Citation Status MEDLINE |
---|
doi: |
10.1371/journal.pone.0279786 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM35557652X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM35557652X | ||
003 | DE-627 | ||
005 | 20231226064635.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1371/journal.pone.0279786 |2 doi | |
028 | 5 | 2 | |a pubmed24n1185.xml |
035 | |a (DE-627)NLM35557652X | ||
035 | |a (NLM)37053300 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wang, Liting |e verfasserin |4 aut | |
245 | 1 | 0 | |a First-line systemic treatment strategies for unresectable hepatocellular carcinoma |b A cost-effectiveness analysis |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 17.04.2023 | ||
500 | |a Date Revised 26.04.2023 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright: © 2023 wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | ||
520 | |a BACKGROUND: Oral multikinase inhibitors and immune checkpoint inhibitors (ICIs) are effective for treating advanced hepatocellular carcinoma (aHCC) but may increase cost. This study compared the cost-effectiveness of oral multikinase inhibitors and ICIs in the first-line treatment of patients with aHCC | ||
520 | |a METHODS: A three-state Markov model was established to study the cost-effectiveness of drug treatment from the perspective of Chinese payers. The key outcomes in this study were total cost, quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER) | ||
520 | |a RESULTS: The total costs and QALYs of sorafenib, sunitinib, donafenib, lenvatinib, sorafenib plus erlotinib, linifanib, brivanib, sintilimab plus IBI305, and atezolizumab plus bevacizumab were $9070 and 0.25, $9362 and 0.78, $33,814 and 0.45, $49,120 and 0.83, $63,064 and 0.81, $74,814 and 0.82, $81,995 and 0.82, $74083 and 0.85, and $104,188 and 0.84, respectively. The drug regimen with the lowest ICER was sunitinib ($551 per QALY), followed by lenvatinib ($68,869 per QALY). For oral multikinase inhibitors, the ICER of lenvatinib, sorafenib plus erlotinib, linifanib and brivanib compared with sunitinib was $779576, $1534,347, $1768,971, and $1963,064, respectively. For ICIs, sintilimab plus IBI305 is more cost effective than atezolizumab plus bevacizumab. The model was most sensitive to the price of sorafenib, the utility of PD, and the price of second-line drugs | ||
520 | |a CONCLUSION: For oral multikinase inhibitors, the order of possible treatment options is sunitinib > lenvatinib > sorafenib plus erlotinib > linifanib > brivanib > donafenib. For ICIs, the order of possible treatment options is sintilimab plus IBI305 > atezolizumab plus bevacizumab | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Sorafenib |2 NLM | |
650 | 7 | |a 9ZOQ3TZI87 |2 NLM | |
650 | 7 | |a lenvatinib |2 NLM | |
650 | 7 | |a EE083865G2 |2 NLM | |
650 | 7 | |a Bevacizumab |2 NLM | |
650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
650 | 7 | |a Sunitinib |2 NLM | |
650 | 7 | |a V99T50803M |2 NLM | |
650 | 7 | |a Erlotinib Hydrochloride |2 NLM | |
650 | 7 | |a DA87705X9K |2 NLM | |
700 | 1 | |a Peng, Ye |e verfasserin |4 aut | |
700 | 1 | |a Qin, Shuxia |e verfasserin |4 aut | |
700 | 1 | |a Wan, Xiaomin |e verfasserin |4 aut | |
700 | 1 | |a Zeng, Xiaohui |e verfasserin |4 aut | |
700 | 1 | |a Li, Sini |e verfasserin |4 aut | |
700 | 1 | |a Liu, Qiao |e verfasserin |4 aut | |
700 | 1 | |a Tan, Chongqing |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t PloS one |d 2006 |g 18(2023), 4 vom: 13., Seite e0279786 |w (DE-627)NLM167327399 |x 1932-6203 |7 nnns |
773 | 1 | 8 | |g volume:18 |g year:2023 |g number:4 |g day:13 |g pages:e0279786 |
856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0279786 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 18 |j 2023 |e 4 |b 13 |h e0279786 |